| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Feb 25, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 25, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 25, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 3, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 15, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 15, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 15, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| E. COLI | Monitoring | 0 | N/A | Dec 20, 2024 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Dec 20, 2024 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Dec 20, 2024 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 21, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 21, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 21, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2024 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 23, 2023 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 21, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 21, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 21, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 21, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 6, 2023 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 6, 2023 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 6, 2023 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 6, 2023 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 6, 2023 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 6, 2023 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 23, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 23, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 23, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 20, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 20, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 20, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 20, 2023 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Feb 11, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 11, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 11, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 11, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 21, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 21, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 21, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 21, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 24, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 24, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 24, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 24, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 25, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Nov 16, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 16, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 16, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0165 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 28, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 28, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 28, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 28, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 17 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Feb 21, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 21, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 21, 2021 | Resolved | N/A |